The British Business Bank has made its largest fund commitment to date with $100m set to support UK life sciences companies.

Investing.com -- Swiss pharmaceutical company Novartis AG (SIX: NOVN) has entered into a partnership with UK-based Relation Therapeutics Ltd., potentially worth up to $1.7 billion, to accelerate the ...

NDAA package revives stalled measures on US outbound investment and biotech, signalling Capitol Hill’s hardened stance ...

What China is accomplishing in R&D “has implications for everyone playing in the R&D or innovation world,” McKinsey’s Fangning Zhang says.

Monday was quite the day for biotech companies developing the next generation of obesity drugs. One of them, Structure ...

Fintel reports that on December 8, 2025, UBS maintained coverage of Legend Biotech Corporation - Depositary Receipt (NasdaqGS ...

We have an emerging new entrant in the increasingly crowded weight loss drug space.

The company appears to be on track to develop a commercialized product through its drug discovery system.

The ASH meeting included positive early results about a Terns drug for chronic myeloid leukemia and a Kura menin-blocker for ...

Precise Bio Inc., a Greensboro-based clinical-stage regenerative medicine company, has announced the world’s first transplant ...

As of Monday, December 08, Legend Biotech Corporation’s LEGN share price has dipped by 8.82%, which has investors questioning if this is right time to buy.

The CEO foresees a "snowball effect" of life sciences companies coming to Dallas, but a couple things need to happen first.